Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2015

Open Access 01-12-2015 | Research

Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi’s sarcoma and non-Kaposi’s cases

Authors: Paola Cordiali-Fei, Elisabetta Trento, Marta Giovanetti, Alessandra Lo Presti, Alessandra Latini, Massimo Giuliani, Giovanna D’Agosto, Valentina Bordignon, Eleonora Cella, Francesca Farchi, Carmela Ferraro, Ilaria Lesnoni La Parola, Carlo Cota, Isabella Sperduti, Antonella Vento, Antonio Cristaudo, Massimo Ciccozzi, Fabrizio Ensoli

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2015

Login to get access

Abstract

Background

Classical Kaposi’s Sarcoma (cKS) is a rare vascular tumor, which develops in subjects infected with Human Herpesvirus-8 (HHV-8). Beside the host predisposing factors, viral genetic variants might possibly be related to disease development. The aim of this study was to identify HHV-8 variants in patients with cKS or in HHV-8 infected subjects either asymptomatic or with cKS-unrelated cutaneous lymphoproliferative disorders.

Methods

The VR1 and VR2 regions of the ORF K1 sequence were analyzed in samples (peripheral blood and/or lesional tissue) collected between 2000 and 2010 from 27 subjects with HHV-8 infection, established by the presence of anti-HHV-8 antibodies. On the basis of viral genotyping, a phylogenetic analysis and a time-scaled evaluation were performed.

Results

Two main clades of HHV-8, corresponding to A and C subtypes, were identified. Moreover, for each subtype, two main clusters were found distinctively associated to cKS or non-cKS subjects. Selective pressure analysis showed twelve sites of the K1 coding gene (VR1 and VR2 regions) under positive selective pressure and one site under negative pressure.

Conclusion

Thus, present data suggest that HHV-8 genetic variants may influence the susceptibility to cKS in individuals with HHV-8 infection.
Literature
1.
Ablashi DV, Chatlynne LG, Whitman JE, Cesarman E. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiology Rev. 2002;15:439–64.CrossRef
2.
3.
Valdarchi C, Serraino D, Cordiali Fei P, Castilletti C, Trento E, Farchi F, et al. Demographic indicators and risk of infection with human herpesvirus type 8 in central italy. Infection. 2007;35:22–5.PubMedCrossRef
4.
Tamburro KM, Yang D, Poisson J, Fedoriw Y, Roy D, Lucas A, et al. Vironome of kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology. 2012;433:220–5.PubMedCentralPubMedCrossRef
5.
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of kaposi sarcoma herpesvirus lytic activation: multicentric castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.PubMedCentralPubMedCrossRef
6.
Trento E, Castilletti C, Ferraro C, Lesnoni La Parola I, Mussi A, Muscardin L, et al. Human herpesvirus 8 infection in patients with cutaneous lymphoproliferative diseases. Arch Dermatol. 2005;141:1235–42.PubMedCrossRef
7.
Kreuter A, Bischoff S, Skrygan M, Wieland U, Brockmeyer NH, Stucker M, et al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides. Arch Dermatol. 2008;144:1011–6.PubMed
8.
Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.PubMedCrossRef
9.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.PubMedCrossRef
10.
11.
Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. 2006;107:2282–90.PubMedCrossRef
12.
Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi’s sarcoma. Eur J Cancer. 2001;37:1251–69.PubMedCrossRef
13.
Taylor GS, Blackbourn DJ. Infectious agents in human cancers: Lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Lett. 2011;305:263–78.PubMedCrossRef
14.
O’Brien TR, Kedes D, Ganem D, Macrae DR, Rosenberg PS, Molden J, et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi’s sarcoma. J Infect Dis. 1999;180:1010–7.PubMedCrossRef
15.
da Silva SR, de Oliveira DE. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett. 2011;305:175–85.PubMedCrossRef
16.
Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM. Convergence of kaposi’s sarcoma-associated herpesvirus reactivation with epstein-barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol. 2010;84:10488–500.PubMedCentralPubMedCrossRef
17.
Cordiali-Fei P, Latini A, Trento E, Zampatti S, Ferraresi V, Cota C, et al. Familial Kaposi’s Sarcoma in HHV8 infected subjects presenting the G-174C allele of the IL-6 promoter: a possible role for EBV? Eur J Dermatol. 2014;24:503–04.PubMed
18.
Brown EE, Fallin D, Ruczinski I, Hutchinson A, Staats B, Vitale F, et al. Associations of classic kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev. 2006;15:926–34.PubMedCrossRef
19.
Gazouli M, Zavos G, Papaconstantinou I, Lukas JC, Zografidis A, Boletis J, et al. The interleukin-6 174 promoter polymorphism is associated with a risk of development of kaposi’s sarcoma in renal transplant recipients. Anticancer Res. 2004;24:1311–4.PubMed
20.
Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, et al. MDM2 and CDKN1A gene polymorphisms and risk of kaposi’s sarcoma in african and caucasian patients. Biomarkers. 2011;16:42–50.PubMedCrossRef
21.
22.
Gonnella R, Santarelli R, Farina A, Granato M, D’Orazi G, Faggioni A, et al. Kaposi Sarcoma Associated Herpervirus (KSHV) induces AKT hyperphosphorilation, bortezomid-resistance and Glut-1 plasma membrane exposure in THP-1 monocytic cell line. J Exp Clin Cancer Res. 2013;32:79–86.PubMedCentralPubMedCrossRef
23.
Jham BC, Montaner SJ. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor: Lessons on dysregulated angiogenesis from a viral oncogene. Cell Biochem. 2010;110:1–9.
24.
Jham BC, Ma T, Hu J, Chaisuparat R, Friedman ER, Pandolfi PP, et al. Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi’s sarcoma. PLoS One. 2011;29:e19103.CrossRef
25.
Liang D, Hu H, Li S, Dong J, Wang X, Wang Y, et al. Oncogenic Herpesvirus KSHV Hijacks BMP-Smad1-Id Signaling to Promote Tumorigenesis. PLoS Pathog. 2014;10:e1004253.PubMedCentralPubMedCrossRef
26.
Tomkowicz B, Singh SP, Lai D, Singh A, Mahalingham S, Joseph J, et al. Mutational analysis reveals an essential role for the LXXLL motif in the transformation function of the human herpesvirus-8 oncoprotein, kaposin. DNA Cell Biol. 2005;24:10–20.PubMedCrossRef
27.
Lagunoff M, Lukac DM, Ganem D. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi’s sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. J Virol. 2001;75:5891–8.PubMedCentralPubMedCrossRef
28.
Tomlinson CC, Damania B. Critical role for endocytosis in the regulation of signaling by the Kaposi’s sarcoma-associated herpesvirus K1 protein. J Virol. 2008;82:6514–23.PubMedCentralPubMedCrossRef
29.
Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res. 2006;66:3658–66.PubMedCrossRef
30.
Wang L, Wakisaka N, Tomlinson CC, DeWire SM, Krall S, Pagano JS, et al. The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 2004;64:2774–81.PubMedCrossRef
31.
Roy D, Sin SH, Lucas A, Venkataramanan R, Wang L, Eason A, et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res. 2013;73:2235–46.PubMedCentralPubMedCrossRef
32.
Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol. 2012;181:1895–9.PubMedCentralPubMedCrossRef
33.
Zong JC, Ciufo DM, Alcendor DJ, Wan X, Nicholas J, Browning PJ, et al. High-level variability in the ORF-K1 membrane protein gene at the left end of the kaposi’s sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J Virol. 1999;73:4156–70.PubMedCentralPubMed
34.
Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, et al. Human herpesvirus type 8 variants circulating in europe, africa and north america in classic, endemic and epidemic kaposi’s sarcoma lesions during pre-AIDS and AIDS era. Virology. 2010;398:280–9.PubMedCrossRef
35.
Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in brazilian amerindians: A hyperendemic population with a new subtype. J Infect Dis. 2000;181:1562–8.PubMedCrossRef
36.
Kasolo C, Monze M, Obel N, Anderson RA, French C, Gompels UA. Sequence analyses of human herpesvirus-8 strains from both African human immunodeficiency virus-negative and -positive childhood endemic Kaposi’s sarcoma show a close relationship with strains identified in febrile children and high variation in the K1 glycoprotein. Gen Virol. 1998;79:3055–65.
37.
Betsem E, Cassar O, Afonso PV, Fontanet A, Froment A, Gessain A. Epidemiology and genetic variability of HHV-8/KSHV in Pygmy and Bantu populations in Cameroon. PLoS Negl Trop Dis. 2014;8:e2851.PubMedCentralPubMedCrossRef
38.
Mancuso R, Biffi R, Valli M, Bellinvia M, Tourlaki A, Ferrucci S, et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi’s sarcoma. J Med Virol. 2008;80:2153–60.PubMedCentralPubMedCrossRef
39.
Zong J, Ciufo DM, Viscidi R, Alagiozoglou L, Tyring S, Rady P, et al. Genotypic analysis at multiple loci across Kaposi’s sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. Clin Virol. 2002;23:119–48.CrossRef
40.
Solivetti FM, Elia F, Latini A, Cota C, Cordiali-Fei P, Di Carlo A. AIDS-Kaposi Sarcoma and Classic Kaposi Sarcoma: are different ultrasound patterns related to different variants? J Exp Clin Cancer Res. 2011;30:40–5.PubMedCentralPubMedCrossRef
41.
Strimmer K, von Haeseler A. Likelihood-mapping: A simple method to visualize phylogenetic content of a sequence alignment. Proc Natl Acad Sci U S A. 1997;94:6815–9.PubMedCentralPubMedCrossRef
42.
Zehender G, Sorrentino C, Lai A, Ebranati E, Gabanelli E, Lo Presti A, et al. Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infect Genet Evol. 2013;17:223–30.PubMedCrossRef
43.
Ciccozzi M, Zehender G, Polat C, Lai A, Kayman T, Sorrentino C, et al. Phylogenetic analysis of HCV-4d in Turkey: the curious case of Kayseri Province. J Med Virol. 2014;86:454–60.PubMedCrossRef
44.
de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21:3797–800.PubMedCrossRef
45.
Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0. Syst Biol. 2010;59:307–21.PubMedCrossRef
46.
Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol. 2004;53:793–808.PubMedCrossRef
47.
Zehender G, Ebranati E, Bernini F, Lo Presti A, Rezza G, Delogu M, et al. Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infect Genet Evol. 2011;11:646–53.PubMedCrossRef
48.
Drummond AJ, Rambaut A, Shapiro B, Pybus OG. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol. 2005;22:1185–92.PubMedCrossRef
49.
50.
51.
Yang Z. PAML: A program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci. 1997;13:555–6.PubMed
52.
Yang Z, Nielsen R, Goldman N, Pedersen AM. Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics. 2000;155:431–49.PubMedCentralPubMed
53.
Nielsen R, Yang Z. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics. 1998;148:929–36.PubMedCentralPubMed
54.
Yang Z, Wong WS, Nielsen R. Bayes empirical Bayes inference of amino acid sites under positive selection. Mol Biol Evol. 2005;22:1107–18.PubMedCrossRef
55.
Anisimova M, Bielawsky JP, Yang Z. Accuracy and power of likelihood ratio test in detecting adptive evolution. Mol Biol Evol. 2001;18:1585–92.PubMedCrossRef
56.
Anisimova M, Bielawsky JP, Yang Z. Accuracy and power of Bayes prediction of amino acid sites under positive selection. Mol Biol Evol. 2002;19:950–8.PubMedCrossRef
57.
Pond SK, Muse SV. Site-to-site variation of synonymous substitution rates. Mol Biol Evol. 2005;22:2375–85.PubMedCrossRef
58.
Kosakovsky Pond SL, Frost SDW. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol. 2005;22:1208–22.PubMedCrossRef
59.
Calabrò ML, Sheldon J, Favero A, Simpson GR, Fiore JR, Gomes E, et al. Seroprevalence of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol. 1998;1:207–13.PubMed
60.
Whitby D, Luppi M, Barozzi P, Boshoff C, Weiss RA, Torelli G. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst. 1998;90:395–7.PubMedCrossRef
61.
Lee BS, Lee SH, Feng P, Chang H, Cho NH, Jung JU. Characterization of the Kaposi’s Sarcoma –associated herpesvirus K1 signalosome. J Virol. 2005;79:12173–84.PubMedCentralPubMedCrossRef
62.
Lee BS, Alvarez X, Ishido S, Lackner AA, Jung JU. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi’s sarcoma-associated herpesvirus K1. J Exp Med. 2000;192:11–21.PubMedCentralPubMedCrossRef
63.
Lee H, Veazey R, Williams K, Li M, Guo J, Neipel F, et al. Deregulation of cell growth by the K1 gene of Kaposi’s sarcoma-associated herpesvirus. Nat Med. 1998;4:435–40.PubMedCrossRef
64.
Prakash O, Swamy OR, Peng X, Tang ZY, Li L, Larson JE, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood. 2005;105:3987–94.PubMedCentralPubMedCrossRef
65.
Samaniego F, Pati S, Karp JE, Prakash O, Bose D. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi’s sarcoma inflammation? J Natl Cancer Inst Monogr. 2001;28:15–23.PubMed
66.
Pileri A, Agostinelli C, Righi S, Fuligni F, Bacci F, Sabattini E, Patrizi A, Pileri SA, Piccaluga PP. Vascular Endothelial Growth Factor A (Vegfa) Expression In Mycosis Fungoides. Histopathology 2014, 26. doi:10.1111/his.12445
Metadata
Title
Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi’s sarcoma and non-Kaposi’s cases
Authors
Paola Cordiali-Fei
Elisabetta Trento
Marta Giovanetti
Alessandra Lo Presti
Alessandra Latini
Massimo Giuliani
Giovanna D’Agosto
Valentina Bordignon
Eleonora Cella
Francesca Farchi
Carmela Ferraro
Ilaria Lesnoni La Parola
Carlo Cota
Isabella Sperduti
Antonella Vento
Antonio Cristaudo
Massimo Ciccozzi
Fabrizio Ensoli
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2015
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-014-0119-0

Other articles of this Issue 1/2015

Journal of Experimental & Clinical Cancer Research 1/2015 Go to the issue

Research

CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1

Research

MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma

Research article

Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases

Research

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

Research article

Developmental pluripotency-associated 4: a novel predictor for prognosis and a potential therapeutic target for colon cancer

Research

Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits